Global Neuromyelitis Optica Drug Market Data Survey Report 2025
Summary
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The global Neuromyelitis Optica Drug market will reach Volume Million USD in 2017 with CAGR xx% 2018-2025. The main contents of the report including:
Global market size and forecast Regional market size, production data and export & import
Key manufacturers (manufacturing sites, capacity and production, product specifications etc.)
Average market price by SUK
Major applications
Key manufacturers are included based on manufacturing sites, capacity and production, product specifications etc.:
Major applications
as follows:
Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The global Neuromyelitis Optica Drug market will reach Volume Million USD in 2017 with CAGR xx% 2018-2025. The main contents of the report including:
Global market size and forecast Regional market size, production data and export & import
Key manufacturers (manufacturing sites, capacity and production, product specifications etc.)
Average market price by SUK
Major applications
Key manufacturers are included based on manufacturing sites, capacity and production, product specifications etc.:
- Pfizer
- FRESENIUS
- TEVA
- SANDOZ
- Intas
- Gyjtrs
- NANG KUANG
- Tianjin Kingyork
- Baxter
- CSL
- Grifols
- Octapharma
- CBOP
Major applications
as follows:
- Acute attack
- Remission prophylactic treatment
- Asia-Pacific
- North America
- Europe
- South America
- Middle East & Africa
1 GLOBAL MARKET OVERVIEW
1.1 Scope of Statistics
1.1.1 Scope of Products
1.1.2 Scope of Manufacturers
1.1.3 Scope of Application
1.1.4 Scope of Regions/Countries
1.2 Global Market Size
2 REGIONAL MARKET
2.1 Regional Production
2.2 Regional Demand
2.3 Regional Trade
3 KEY MANUFACTURERS
3.1 Pfizer
3.1.2 Company Information
3.1.2 Product Specifications
3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.2 FRESENIUS
3.2.1 Company Information
3.2.2 Product Specifications
3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.3 TEVA
3.3.1 Company Information
3.3.2 Product Specifications
3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.4 SANDOZ
3.4.1 Company Information
3.4.2 Product Specifications
3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.5 Intas
3.5.1 Company Information
3.5.2 Product Specifications
3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.6 Gyjtrs
3.6.1 Company Information
3.6.2 Product Specifications
3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.7 NANG KUANG
3.7.1 Company Information
3.7.2 Product Specifications
3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.8 Tianjin Kingyork
3.8.1 Company Information
3.8.2 Product Specifications
3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.9 Baxter
3.9.1 Company Information
3.9.2 Product Specifications
3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.10 CSL
3.10.1 Company Information
3.10.2 Product Specifications
3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.11 Grifols
3.12 Octapharma
3.13 CBOP
4 MAJOR APPLICATION
4.1 Acute attack
4.1.1 Overview
4.1.2 Acute attack Market Size and Forecast
4.2 Remission prophylactic treatment
4.2.1 Overview
4.2.2 Remission prophylactic treatment Market Size and Forecast
5 MARKET PRICE
5.1 Overview
5.2 Price by SUK
6 CONCLUSION
1.1 Scope of Statistics
1.1.1 Scope of Products
1.1.2 Scope of Manufacturers
1.1.3 Scope of Application
1.1.4 Scope of Regions/Countries
1.2 Global Market Size
2 REGIONAL MARKET
2.1 Regional Production
2.2 Regional Demand
2.3 Regional Trade
3 KEY MANUFACTURERS
3.1 Pfizer
3.1.2 Company Information
3.1.2 Product Specifications
3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.2 FRESENIUS
3.2.1 Company Information
3.2.2 Product Specifications
3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.3 TEVA
3.3.1 Company Information
3.3.2 Product Specifications
3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.4 SANDOZ
3.4.1 Company Information
3.4.2 Product Specifications
3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.5 Intas
3.5.1 Company Information
3.5.2 Product Specifications
3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.6 Gyjtrs
3.6.1 Company Information
3.6.2 Product Specifications
3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.7 NANG KUANG
3.7.1 Company Information
3.7.2 Product Specifications
3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.8 Tianjin Kingyork
3.8.1 Company Information
3.8.2 Product Specifications
3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.9 Baxter
3.9.1 Company Information
3.9.2 Product Specifications
3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.10 CSL
3.10.1 Company Information
3.10.2 Product Specifications
3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
3.11 Grifols
3.12 Octapharma
3.13 CBOP
4 MAJOR APPLICATION
4.1 Acute attack
4.1.1 Overview
4.1.2 Acute attack Market Size and Forecast
4.2 Remission prophylactic treatment
4.2.1 Overview
4.2.2 Remission prophylactic treatment Market Size and Forecast
5 MARKET PRICE
5.1 Overview
5.2 Price by SUK
6 CONCLUSION
LIST OF TABLES
Tab REGIONAL PRODUCTION 2011-2017 (VALUE)
Tab Regional Production 2011-2017 (Volume)
Tab Regional Demand and CAGR 2011-2017 (Value)
Tab Regional Demand and CAGR 2011-2017 (Volume)
Tab Regional Demand Forecast and CAGR 2018-2025 (Value)
Tab Regional Demand Forecast and CAGR 2018-2025 (Volume)
Tab Regional Export 2011-2017 (Value)
Tab Regional Export 2011-2017 (Volume)
Tab Regional Import 2011-2017 (Value)
Tab Regional Import 2011-2017 (Volume)
Tab Sales Revenue, Volume, Price, Cost and Margin of Pfizer
Tab Sales Revenue, Volume, Price, Cost and Margin of FRESENIUS
Tab Sales Revenue, Volume, Price, Cost and Margin of TEVA
Tab Sales Revenue, Volume, Price, Cost and Margin of SANDOZ
Tab Sales Revenue, Volume, Price, Cost and Margin of Intas
Tab Sales Revenue, Volume, Price, Cost and Margin of Gyjtrs
Tab Sales Revenue, Volume, Price, Cost and Margin of NANG KUANG
Tab Sales Revenue, Volume, Price, Cost and Margin of Tianjin Kingyork
Tab Sales Revenue, Volume, Price, Cost and Margin of Baxter
Tab Sales Revenue, Volume, Price, Cost and Margin of CSL
Tab Sales Revenue, Volume, Price, Cost and Margin of Grifols
Tab Sales Revenue, Volume, Price, Cost and Margin of Octapharma
Tab Sales Revenue, Volume, Price, Cost and Margin of CBOP
Tab Market Price by Region
Tab Market Price by Manufacturers
Tab Market Price by Application
Tab Price by SUK (Popular Goods on the Market)
Tab REGIONAL PRODUCTION 2011-2017 (VALUE)
Tab Regional Production 2011-2017 (Volume)
Tab Regional Demand and CAGR 2011-2017 (Value)
Tab Regional Demand and CAGR 2011-2017 (Volume)
Tab Regional Demand Forecast and CAGR 2018-2025 (Value)
Tab Regional Demand Forecast and CAGR 2018-2025 (Volume)
Tab Regional Export 2011-2017 (Value)
Tab Regional Export 2011-2017 (Volume)
Tab Regional Import 2011-2017 (Value)
Tab Regional Import 2011-2017 (Volume)
Tab Sales Revenue, Volume, Price, Cost and Margin of Pfizer
Tab Sales Revenue, Volume, Price, Cost and Margin of FRESENIUS
Tab Sales Revenue, Volume, Price, Cost and Margin of TEVA
Tab Sales Revenue, Volume, Price, Cost and Margin of SANDOZ
Tab Sales Revenue, Volume, Price, Cost and Margin of Intas
Tab Sales Revenue, Volume, Price, Cost and Margin of Gyjtrs
Tab Sales Revenue, Volume, Price, Cost and Margin of NANG KUANG
Tab Sales Revenue, Volume, Price, Cost and Margin of Tianjin Kingyork
Tab Sales Revenue, Volume, Price, Cost and Margin of Baxter
Tab Sales Revenue, Volume, Price, Cost and Margin of CSL
Tab Sales Revenue, Volume, Price, Cost and Margin of Grifols
Tab Sales Revenue, Volume, Price, Cost and Margin of Octapharma
Tab Sales Revenue, Volume, Price, Cost and Margin of CBOP
Tab Market Price by Region
Tab Market Price by Manufacturers
Tab Market Price by Application
Tab Price by SUK (Popular Goods on the Market)
LIST OF FIGURES
Fig Global Neuromyelitis Optica Drug Market Size and CAGR 2011-2017 (Value)
Fig Global Neuromyelitis Optica Drug Market Size and CAGR 2011-2017 (Volume)
Fig Global Neuromyelitis Optica Drug Market Forecast and CAGR 2018-2025 (Value)
Fig Global Neuromyelitis Optica Drug Market Forecast and CAGR 2018-2025 (Volume)
Fig Acute attack Market Size and CAGR 2011-2017 (Value)
Fig Acute attack Market Size and CAGR 2011-2017 (Volume)
Fig Acute attack Market Forecast and CAGR 2018-2025 (Value)
Fig Acute attack Market Forecast and CAGR 2018-2025 (Volume)
Fig Remission prophylactic treatment Market Size and CAGR 2011-2017 (Value)
Fig Remission prophylactic treatment Market Size and CAGR 2011-2017 (Volume)
Fig Remission prophylactic treatment Market Forecast and CAGR 2018-2025 (Value)
Fig Remission prophylactic treatment Market Forecast and CAGR 2018-2025 (Volume)
Fig Global Market Price 2011-2017
Fig Global Market Price 2018-2025
Fig Global Neuromyelitis Optica Drug Market Size and CAGR 2011-2017 (Value)
Fig Global Neuromyelitis Optica Drug Market Size and CAGR 2011-2017 (Volume)
Fig Global Neuromyelitis Optica Drug Market Forecast and CAGR 2018-2025 (Value)
Fig Global Neuromyelitis Optica Drug Market Forecast and CAGR 2018-2025 (Volume)
Fig Acute attack Market Size and CAGR 2011-2017 (Value)
Fig Acute attack Market Size and CAGR 2011-2017 (Volume)
Fig Acute attack Market Forecast and CAGR 2018-2025 (Value)
Fig Acute attack Market Forecast and CAGR 2018-2025 (Volume)
Fig Remission prophylactic treatment Market Size and CAGR 2011-2017 (Value)
Fig Remission prophylactic treatment Market Size and CAGR 2011-2017 (Volume)
Fig Remission prophylactic treatment Market Forecast and CAGR 2018-2025 (Value)
Fig Remission prophylactic treatment Market Forecast and CAGR 2018-2025 (Volume)
Fig Global Market Price 2011-2017
Fig Global Market Price 2018-2025
